Broad vs Narrow Spectrum Antibiotics: Key Differences

Antibiotic resistance emerges from microbial adaptation to antibiotic overuse, creating a global health crisis causing 2.8 million infections and over 35,000 deaths annually in the US. Five resistance mechanisms exist: enzymatic inactivation, decreased permeability, efflux pumps, antibiotic binding decoys, and target site alteration. Four major gram-negative MDROs are: ESBL-producing Enterobacteriaceae (resistant to penicillins, cephalosporins, aztreonam), CRE/KPC (carbapenem-resistant), extremely drug-resistant Pseudomonas aeruginosa, and Acinetobacter baumannii. Risk factors include prolonged healthcare exposure, recent antimicrobial use, indwelling devices, immunosuppression, and chronic dialysis. The CDC classifies Acinetobacter and CRE as urgent threats, while ESBL and MDR Pseudomonas are serious threats.

Antimicrobial resistance is a natural evolutionary process where approximately one in 10 million to one in a hundred billion microbes possess pre-existing resistance mutations. Under antibiotic selective pressure, resistant microbes survive and reproduce, increasing their population over time. Five resistance mechanisms exist: prevention of drug uptake/efflux pumps, drug modification/inactivation by enzymes, target modification (evolving different structures), target mimicry (producing drug-binding molecules), and target overproduction overwhelming drug concentrations. Multi-drug resistant (MDR) 'superbugs' have evolved multiple resistance mechanisms, causing over 2 million infections and 23,000 deaths annually in the U.S. Examples include MRSA, VRE, and CRE. In 2016, a Nevada woman died from pan-resistant CRE infection resistant to all antibiotics.

Bacteria survive through mutations and horizontal gene transfer, acquiring resistance genes from other bacteria. Resistance mechanisms include destroying antibiotics, pumping them out, or substituting cellular components. These genetic elements spread easily in hospitals where antibiotics concentrate. Multi-drug resistance emerged as bacteria accumulated resistance to multiple structurally unrelated antibiotics simultaneously, creating superbugs that evade multiple treatments.

Antibiotic resistance occurs when bacteria evolve mechanisms to survive antibiotic treatment. Overuse of antibiotics contributes to resistance development: when antibiotics are used frequently or inappropriately (such as for viral infections), bacteria that survive develop resistance mechanisms. Bacteria can develop resistance through producing enzymes that break down antibiotics, changing cell wall structure, or pumping antibiotics out of the cell. This is a major global health concern. The progression of resistance in Staphylococcus aureus demonstrates this: penicillin was effective in the 1940s, but resistant strains emerged requiring methicillin, and later methicillin-resistant S. aureus (MRSA) appeared, resistant to multiple antibiotic classes.

Antibiotic resistance develops through natural selection when antibiotics kill susceptible bacteria but leave resistant ones to multiply. Incomplete treatment courses (stopping antibiotics when symptoms improve) allow partially resistant bacteria to survive and develop stronger resistance. These bacteria then pass resistance genes to other bacteria. The process is accelerated by overuse of antibiotics, treating viral infections with antibiotics, and using antibiotics as growth promoters in agriculture. This creates a selection pressure that drives the evolution of multidrug-resistant superbacteria.

The human lower intestinal microbiome is extraordinarily complex, with only 20% of organisms successfully cultured in vitro. Most are anaerobes that cannot survive in oxygen-rich laboratory conditions. Antibiotics cause profound perturbations to this ecosystem, creating conditions that predispose patients to Clostridioides difficile infection (CDI). C. difficile produces highly resistant endospores that enable environmental survival and spread through hospital settings. This disruption transforms the microbiome from a protective barrier into an ecological niche where opportunistic pathogens can colonize, multiply, and cause difficult-to-treat infections.

This section covers the human microbiome and infection dynamics. The microbiome contains 10^14 microbes versus 10^13 human cells. Most body sites are colonized, except sterile locations like blood and CSF. Opportunistic infections occur when normal defenses fail (wounds, improper hygiene). Microflora disturbances from antibiotics kill beneficial bacteria, allowing pathogens like C. diff and yeast to proliferate. This demonstrates how antibiotic use can trigger secondary infections by disrupting normal microbial balance.

C. difficile is the most common Clostridia species, causing disease only when normal gut flora is disrupted by antibiotics. It produces two toxins: Toxin A (enterotoxin causing inflammation and watery diarrhea) and Toxin B (cytotoxin causing actin depolymerization and cell necrosis—more potent than Toxin A). This leads to pseudomembrane formation in the colon. Severe cases present with toxic megacolon (abdominal pain, distension, bloody diarrhea, fever, shock). Diagnosis uses NAAT/PCR or toxin assays. Treatment includes oral vancomycin or metronidazole; severe cases require fidaxomicin, surgery, or fecal transplant. Prevention requires soap-and-water handwashing (alcohol doesn't kill spores).

C. difficile presents along a severity spectrum. Uncomplicated cases feature acute watery diarrhea, abdominal pain, low-grade fever, and leukocytosis. Severe pseudomembranous colitis involves diffuse abdominal pain, distension, high fever, hypovolemia, lactic acidosis, and extreme leukocytosis (up to 40,000/μL). Complications include bowel perforation, sepsis, peritonitis, and toxic megacolon, potentially requiring subtotal colectomy. Risk factors include recent antibiotics, hospitalization, advanced age, and close contact with infected individuals.

PPI use dramatically increases infection risks through microbiome disruption. Studies show over 5.5 times higher C. difficile infection risk in PPI users, with C. diff, Campylobacter, and Salmonella as primary culprits. These organisms are normal gut residents but become pathogenic during dysbiosis. The FDA issued warnings in 2012 about C. difficile risks. PPIs carry significantly higher risks than H2 blockers, which are weaker acid suppressors. This pattern illustrates how PPI-induced dysbiosis transforms commensal bacteria into pathogens.

Three main methods exist for testing antibiotic susceptibility: (1) Disk diffusion (Kirby-Bauer) - most commonly used in Bolivia and hospitals, (2) Broth dilution - provides quantitative results and Minimum Inhibitory Concentration (MIC), (3) E-test - combines features of both methods. The Kirby-Bauer method involves placing antibiotic-impregnated disks on agar plates inoculated with bacteria. After incubation at 35°C for 18-24 hours, inhibition zone sizes indicate susceptibility. The broth dilution method uses serial antibiotic concentrations in broth tubes to determine the lowest concentration that prevents bacterial growth.

This video demonstrates two primary methods for determining bacterial susceptibility to antibiotics: the Kirby-Bauer disk diffusion method, which involves applying antibiotic-impregnated disks to inoculated Mueller-Hinton agar plates and measuring inhibition zone diameters using EUCAST reference tables to classify results as susceptible, intermediate, or resistant; and the E-test method, which uses a gradient strip containing varying antibiotic concentrations to determine the minimum inhibitory concentration (MIC) by measuring where the inhibition zone intersects the concentration gradient. Results are interpreted using EUCAST guidelines available at www.miaukot.org and www.kosztorysy.edu.pl.

The Kirby-Bauer disc diffusion test determines bacterial susceptibility to antimicrobials by placing filter paper discs containing antibiotics on an agar plate inoculated with a standardized bacterial suspension; antimicrobials diffuse outward from the discs, creating concentration gradients that inhibit bacterial growth at varying distances, with the resulting inhibitory zone diameters measured and compared against CLSI interpretive criteria to classify organisms as susceptible, intermediate, or resistant.

Antimicrobial susceptibility testing is divided into diffusion methods (Kirby-Bauer disk diffusion, E-test) and dilution methods (tube or agar dilution). Disk diffusion is the most commonly used routine method. For Kirby-Bauer testing, bacteria are inoculated to achieve 0.5 McFarland turbidity (10^8 organisms/ml). Antibiotic-impregnated disks are placed on Mueller-Hinton agar plates. After 18-24 hours incubation, inhibition zone diameters are measured and compared to CLSI or EUCAST guidelines. E-test provides minimal inhibitory concentration (MIC) values by gradient diffusion. MIC is the lowest concentration preventing visible bacterial growth, indicating bacteriostatic activity.

The Kirby-Bauer disk diffusion technique determines antibiotic susceptibility by placing antibiotic-impregnated discs on a bacterial lawn and measuring zones of inhibition, where larger zones indicate greater susceptibility; the minimum inhibitory concentration (MIC) is determined through serial dilution tests that identify the lowest antibiotic concentration preventing bacterial growth, ensuring optimal therapeutic dosing while minimizing side effects.